SARS-CoV-2 Vaccination Associated Transverse Myelitis: A Case Report
Published: September 1, 2022 | DOI: https://doi.org/10.7860/JCDR/2022/58310.16916
Bhargavi Kumar, Saravanan Thangavelu, Sakthivel Selvam, Vikranth Raja, Aditya Chandran
1. Associate Professor, Department of Medicine, PSG Institute of Medical Sciences and Research, Coimbatore, Tamil Nadu, India.
2. Professor and Head, Department of Medicine, PSG Institute of Medical Sciences and Research, Coimbatore, Tamil Nadu, India.
3. Student CRRI, Department of Medicine, PSG Institute of Medical Sciences and Research, Coimbatore, Tamil Nadu, India.
4. Student CRRI, Department of Medicine, PSG Institute of Medical Sciences and Research, Coimbatore, Tamil Nadu, India.
5. Student CRRI, Department of Medicine, PSG Institute of Medical Sciences and Research, Coimbatore, Tamil Nadu, India.
Correspondence
Bhargavi Kumar,
G 802,Purva Amaiti, Trichy Road, Singanallur, Cimbatore-641005, Tamil Nadu, India.
E-mail: kmcbhargavi@gmail.com
While policy makers around the globe have meticulously organised mass immunisation against Coronavirus Disease 2019 (COVID-19), its safety concerns and adverse events that need prompt evaluation are also emerging. Acute Transverse Myelitis (TM) is a rare neurological phenomenon where motor, sensory or autonomic disturbance occurs as a result of spinal cord injury. The aetiology of transverse myelitis is thought to be immune-mediated as a result of infection, parainfectious disorder, autoimmune disease or malignancy. Though a rare disease, acute TM warrants prompt recognition and aggressive therapy for favourable neurological patient outcomes. Hereby, authors presented this case of a 61-year-old male patient who developed symptoms of acute TM, 20 days after receiving an adenovirus vectored ChAdOx1 nCoV-19 vaccine against SARS-CoV-2. The patient was treated with intravenous steroids, supportive care with Foley’s catheterisation and his weakness and bladder control improved over 1 week.
[
FULL TEXT ] | [ PDF]